Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive CNY 30 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd
September 21, 2021
Share
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced a private placement of common shares for gross proceeds of CNY 30,000,000 on September 22, 2021. The transaction will include participation from existing investor, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. to retain 100% stake in the company. Post the closing, the registered capital of the company will increase from CNY 107,457,627.12 to CNY 110,000,000. The transaction has been approved by the board of directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd at the eleventh meeting of the seventh board of directors and the eighth meeting of the seventh board of supervisors.
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive CNY 30 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD 
